Background:
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
Objective:
To find the safest and most effective dose of tivozanib to treat CCA and learn its overall response rate.
Eligibility:
Adults ages 18 and older with CCA not removable with surgery and have been treated with at least one type of chemotherapy.
Design:
Participants will be screened with the following:
Medical history
Physical exam
Assessment of their ability to do daily activities
Medicine review
Blood tests, including thyroid function tests
Urine tests
Electrocardiogram, to check heart function
Pregnancy test, if needed
Tumor biopsy, if needed
Computed tomography scans
Magnetic resonance imaging, if needed
Some screening tests may be repeated during the study.
Participants will be asked to enroll in protocol #13C0176. This will allow any remaining tumor or blood samples to be used in future research.
Participants will take tivozanib by mouth, once a day for 21 days per cycle or every other day per cycle. Each cycle is 28 days. They can take the drug until they have bad side effects, their CCA gets worse, or if they become pregnant. They will record their blood pressure twice daily at home. They will also keep a medication diary of each dose of tivozanib they take and any side effects.
Participants will have study visits before starting each new cycle and every 8 weeks. They will also have a follow-up visit 30 days after treatment ends at NIH, or if they are unable to come to NIH by phone, videocall, or other NIH-approved platform. Then they will be contacted 6 and 12 months later, and then once a year.

开始日期2022-03-04

申办/合作机构

National Cancer Institute

NCT05000294 / Recruiting临床1/2期IIT

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies.
Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment of several immunologically "cold" tumors such as prostate cancer, biliary tract cancers, soft tissue sarcomas, well-differentiated neuroendocrine tumors, microsatellite stable colorectal cancer, pancreatic cancer, and non-triple negative breast cancer.
Vascular endothelial growth factor (VEGF) is thought to play a key role in modulating the anti-tumor immune response. Vascular endothelial growth factor (VEGF) is secreted by tumors and leads to endothelial cell proliferation, vascular permeability, and vasodilation. This in turn leads to the development of an abnormal vasculature with excessive permeability and poor blood flow, limiting immune surveillance. In addition, VEGF inhibits dendritic cell differentiation, limiting the presentation of tumor antigens to CD4 and CD8 T cells. Vascular endothelial growth factor (VEGF). VEGF tyrosine kinase inhibitors (TKIs) VEGF-TKIs are currently utilized in the treatment of a variety of malignancies and are widely utilized in combination with checkpoint blockade in the treatment of clear cell kidney cancer.
Through the inhibition of VEGF, it may be possible to potentiate the effect of immune checkpoint blockade even in tumors which have traditionally been thought to be unresponsive to immunotherapy. This study aims to evaluate the combination of the immune checkpoint inhibitor atezolizumab and the VEGF-TKI tivozanib in a variety of tumors which have a low response rate to checkpoint inhibitor therapy alone.

开始日期2021-12-07

申办/合作机构

University of Florida

[+2]

100 项与替沃扎尼相关的临床结果

登录后查看更多信息

100 项与替沃扎尼相关的转化医学

登录后查看更多信息

100 项与替沃扎尼相关的专利（医药）

登录后查看更多信息

159

项与替沃扎尼相关的文献（医药）

2024-02-01·Urologic oncology

Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma

Article

作者: Choi, Briana M ; Recio-Boiles, Alejandro ; Kreutzfeldt, Jordyn J ; Obeng-Kusi, Mavis ; Abraham, Ivo ; Estrada-Mendizabal, Ricardo J

INTRODUCTION:

Deciding on the optimal second-line (2L) treatment for metastatic clear-cell renal cell carcinoma (ccRCC) remains challenging due to the limited information comparing each of the available options and the influence of the newly expanding first-line (1L) agents.

PATIENTS AND METHODS:

We identified phase II/III randomized controlled trials (RCTs) evaluating 2L treatments in metastatic ccRCC. This Network Meta-analysis (NMA) evaluates the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and severe adverse events (SAE). We used normal likelihood model to incorporate log hazard ratios (HRs), odds ratios (OR), and 95%-confidence-intervals (CI). Treatment p-scores were used for ranking. Data was analyzed in a fixed-effects model using the netmeta package in R v.1.5-0.

RESULTS:

All therapies demonstrated some benefits over placebo. Lenvatinib + everolimus ranked first for OS (HR = 0.44; 95%CI = 0.24-0.82; p-score = 0.92), PFS (HR = 0.13; 95%CI = 0.07-0.24, p-score = 0.98), and ORR (OR = 35.95; 95%CI = 11.55-111.87; p-score = 0.93) compared to placebo, though with a higher SAE (OR = 5.27; p-score = 0.23). Cabozantinib ranked second for OS (HR = 0.57, p-score = 0.80), PFS (HR = 0.19; p-score = 0.86), and ORR (OR = 27.24, p-score = 0.84). Nivolumab was third for ORR (p-score = 0.79), fourth for OS (p-score = 0.69), fifth for PFS (p-score = 0.61), and last for SAE (p-score = 0.83). Lenvatinib monotherapy ranked worst SAE (OR = 5.89, p-score = 0.17) and third for OS and PFS. The latest drug, tivozanib, was sixth for PFS, OS, and ORR. The NMA matrix revealed no differential OS benefit between cabozantinib, lenvatinib + everolimus, and nivolumab. Other regimens had no significant OS benefit when compared to placebo.

CONCLUSION:

Based on OS and PFS, the lenvtatinib + everolimus combination yielded superior, followed by cabozantinib and Lenvatinib monotherapies; all were limited by a worse SAE profile. Nivolumab and pazopanib had the lowest odds of SAEs.

2024-01-01·Journal of the Chinese Medical Association : JCMA

Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis

Review

作者: Hsieh, Fang-I ; Chen, Jin-Hua ; Chen, Yen-Chou

Background::

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) are a common cancer treatment. However, the pharmacologic characteristics of VEGF-TKIs may influence cardiovascular risks. The relative risks of major adverse cardiovascular events (MACEs) associated with VEGF-TKIs are poorly understood.

Methods::

We searched PubMed, Embase, and ClinicalTrials.gov from inception until August 31, 2021, for phase II/III randomized controlled trials of 11 VEGF-TKIs (axitinib, cabozantinib, lenvatinib, pazopanib, ponatinib, ripretinib, regorafenib, sorafenib, sunitinib, tivozanib, and vandetanib). The endpoints were heart failure, thromboembolism, and cardiovascular death. The Mantel-Haenszel method was used to calculate the risk of VEGF-TKI among users by comparing it to nonusers. Pairwise meta-analyses with a random-effects model were used to estimate the risks of the various VEGF-TKIs. We estimated ranked probability with a P-score and assessed credibility using the Confidence in Network Meta-Analysis framework.

Results::

We identified 69 trials involving 30 180 patients with cancer. The highest risk of MACEs was associated with high-potency tivazonib (odds ratio [OR]: 3.34), lenvatinib (OR: 3.26), and axitinib (OR: 2.04), followed by low-potency pazopanib (OR: 1.79), sorafenib (OR: 1.77), and sunitinib (OR: 1.66). The risk of heart failure significantly increased in association with less-selective sorafenib (OR: 3.53), pazopanib (OR: 3.10), and sunitinib (OR: 2.65). The risk of thromboembolism significantly increased in association with nonselective lenvatinib (OR: 3.12), sorafenib (OR: 1.54), and sunitinib (OR: 1.53). Higher potency (tivozanib, axitinib) and lower selectivity (sorafenib, vandetanib, pazopanib, sunitinib) were associated with a higher probability of heart failure. Low selectivity (lenvatinib, cabozantinib, sorafenib, sunitinib) was associated with a higher probability of thromboembolism.

Conclusion::

Higher-potency and lower-selectivity VEGF-TKIs may influence the risks of MACEs, heart failure, and thromboembolism. These findings may facilitate evidence-based decision-making in clinical practice.

2023-10-19·bioRxiv : the preprint server for biology

Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism.

作者: Behr, Eliot ; Barekatain, Yasaman ; Muller, Florian L ; Asara, John M ; Qian, Wubin ; Barthel, Floris P ; Chen, Yining ; DePinho, Ronald A ; Millward, Steve W ; Chaurasia, Surendra ; Lin, Yu-Hsi ; Hsu, Wen-Hao ; Khadka, Sunada ; Tran, Theresa ; Chen, Yi-An ; Guo, Sheng ; Uddin, Nasir ; Ackroyd, Jeffrey ; Yan, Victoria ; Georgiou, Dimitra K ; Arthur, Kenisha ; Sheng, Yanghui ; Chang, Qing ; Poral, Anton

Tumor angiogenesis is a cancer hallmark, and its therapeutic inhibition has provided meaningful, albeit limited, clinical benefit. While anti-angiogenesis inhibitors deprive the tumor of oxygen and essential nutrients, cancer cells activate metabolic adaptations to diminish therapeutic response. Despite these adaptations, angiogenesis inhibition incurs extensive metabolic stress, prompting us to consider such metabolic stress as an induced vulnerability to therapies targeting cancer metabolism. Metabolomic profiling of angiogenesis-inhibited intracranial xenografts showed universal decrease in tricarboxylic acid cycle intermediates, corroborating a state of anaplerotic nutrient deficit or stress. Accordingly, we show strong synergy between angiogenesis inhibitors (Avastin, Tivozanib) and inhibitors of glycolysis or oxidative phosphorylation through exacerbation of anaplerotic nutrient stress in intracranial orthotopic xenografted gliomas. Our findings were recapitulated in GBM xenografts that do not have genetically predisposed metabolic vulnerabilities at baseline. Thus, our findings cement the central importance of the tricarboxylic acid cycle as the nexus of metabolic vulnerabilities and suggest clinical path hypothesis combining angiogenesis inhibitors with pharmacological cancer interventions targeting tumor metabolism for GBM tumors.

项与替沃扎尼相关的新闻（医药）

2024-06-13

·PipelineReview

LG Chem company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.

– LG Chem to embark on developing Next-Generation Immune Checkpoint Inhibitors to Provide Solid Tumor Treatment Solutions – – LG Chem and AVEO Oncology continuing to advance its shared vision of becoming a leading global oncology company – BOSTON, MA, USA I June 13, 2024 I LG Chem and AVEO Oncology, an LG Chem company, announced that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109 (NCT06332755; LG project code LR19155), LG Chem’s first proprietary anti-cancer investigational drug candidate. LG Chem will be collaborating closely with AVEO Oncology, its wholly owned subsidiary, that specializes in oncology development and commercialization, to advance strategies for late-stage clinical development and regulatory approval. This is a Phase 1, multi-center, open-label, non-randomized, dose escalation study designed to determine the recommended Phase 2 dose of LB-LR1109 and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, and pharmacodynamics of LB-LR1109, and its potential impact on quality of life. The study is evaluating participants with unresectable and metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma who have progressed on standard of care treatment options. In preclinical studies of LB-LR1109, LG Chem observed dose-dependent anti-cancer effects. Subsequently, the company received approval for an Investigational New Drug application from the U.S. Food and Drug Administration (FDA) in December last year. Leukocyte Immunoglobulin Like Receptor B-1 (LILRB1), a protein released by cancer cells to prevent immune cell attacks, is commonly expressed on the surfaces of several immune cells, including T cells, natural killer cells (NK cells), and macrophages (phagocytic cells). This mechanism is believed to work by activating the tumor-eradicating cells such as T cells, NK cells, and macrophages simultaneously. i This simultaneous activation of overall immune cell functions may differentiate it from existing therapies that focus on single immune cells like T cells. “We are excited to partner with LG Chem on their first proprietary anti-cancer compound,” said Dr. Alex Spira, Director of Next Oncology of Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program. “There is a high unmet need for patients that have progressed on standard of care treatment which necessitates the need to explore novel immune checkpoint inhibitors such as LB-LR1109.” Jeewoong Son, MD, President of LG Chem Life Sciences Company, stated, “We are focusing all our capabilities to provide innovative treatments that will be recognized by medical professionals and patients, as we aim to improve the lives of patients with cancer. While this is the first oncology compound from LG Chem, we are developing a robust pipeline that target novel oncology targets. We will continue to offer differentiated treatment options in the oncology field, where there is the greatest unmet medical need.” The advancement of this program into the clinic brings LG Chem and AVEO Oncology one step closer to realizing our vision of becoming one of the world’s leading oncology companies with a robust clinical pipeline of innovative therapies. About AVEO Pharmaceuticals, Inc. AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. For more information, please visit www.aveooncology.com . About LG Chem, Ltd. and LG Chem Life Sciences LG Chem, Ltd. (LG Chem) is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem Life Sciences develops, manufactures, and globally commercializes pharmaceutical products, with a focus on Oncology, Immunology, and Metabolic diseases. Our mission is to transform people’s lives through inspiring science and leading innovation. For more information, please visit www.lgchem.com . SOURCE: LG Chem

免疫疗法临床1期

2024-05-08

·PRNewswire

Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

PRINCETON, N.J. and TOKYO, May 8, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024. Age-related macular degeneration (AMD) is a leading cause of severe vision loss for people aged 50 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals. With the increase in life expectancy, the number of reported cases of AMD will increase, continuing to add to the substantial burden already on patients, caretakers, and on health care system. Neovascular (wet) AMD (nAMD) is characterized by abrupt central vision loss caused by abnormal blood vessel growth and leakage in the macular area, the part of the retina that is responsible for everyday activities such as reading, driving, and writing. These vessels are fragile, leak fluid, can easily break and cause bleeding. nAMD accounts for roughly 10% of all AMD cases, but almost 90% of AMD-related central vision loss. "Today, we are excited to present the preclinical data of the nano-crystalized tivozanib after application as eye drops which set the stage for our completed phase 1 clinical trial in Japanese patients with neovascular age-related macular degeneration," said Judit Baffi, lead Clinical Science Ophthalmologist at Kyowa Kirin. "We look forward to sharing more data about this novel investigational agent as they become available and highlighting its different route of delivery in nAMD which has the potential of lessening the burden for patients and treatment teams in this vision threatening disease." Separate phase 2 clinical trial, multi-center, randomized, double-masked, parallel group studies of tivozanib eye drops (KHK4951) aimed to investigate the efficacy and safety of KHK4951 in patients with nAMD and diabetic macular edema (DME) are both currently recruiting patients. Abstract Title: Pre-clinical ocular pharmacokinetics and efficacy of a novel Tivozanib eye drop for neovascular age-related macular degeneration Author: Kyosuke Satake, MS, Miwa Watanabe, PhD., Shinya Horita, PhD., MBA, Shoko Koshiba, PhD., Yoshiaki Otsu, Masanori Hiura, MS, Harunobu Tahara, PhD., Toru Amano, PhD. Presentation: Wednesday, May 8th 2:15 – 4:00 PM PST Location: Exhibit Hall, Quadrant A, Poster A0009 In this pre-clinical study, nano-crystalized formulations of tivozanib (nTivo) was ocularly instilled to rabbits and monkeys, and ocular pharmacokinetics and efficacy were evaluated. In pigmented rabbits, nTivo eye drops showed up to 9.5 times higher drug delivery eﬃciency to the retina/choroid compared to microcrystal formulations. Repeated ocular installation of nTivo eye drops increased exposure in the retina/choroid compared to single ocular installation in pigmented rabbits. The elimination half-life (t1/2) of tivozanib was longer in the retina/choroid compared to serum. Pigmented rabbits showed higher exposure and longer t1/2 in the retina/choroid compared to albino rabbits. In laser-induced choroidal neovascularization model in monkeys, nTivo eye drops decreased neovascularization lesion area and showed increased drug concentrations in the choroid and retina with higher dosing frequency. In vivo data suggest that nTivo eye drops could be a potential therapeutic agent for treating posterior eye diseases. The accumulation and sustained exposure to tivozanib in the choroid and retina may be related to melanin-binding properties and nano-crystallized formulation of tivozanib. About tivozanib Tivozanib, the active ingredient of KHK4951 is a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI) discovered and developed by Kyowa Kirin. KHK4951, an investigational product, is a novel nano-crystalized tivozanib eye drop designed to be delivered to the posterior ocular tissues and is being developed as a potential treatment option for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). An oral formulation of tivozanib approved for a different indication currently marketed as FOTIVDA® by AVEO Pharmaceuticals, Inc., an LG Chem company, and in Europe by EUSA Pharma (UK) Ltd., a Recordati Group Company. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: SOURCE Kyowa Kirin

上市批准临床1期临床结果临床2期

2024-04-02

·PRNewswire

Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

PRINCETON, N.J. and TOKYO, April 2, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024. Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals. With the increase in life expectancy, the number of reported cases of AMD is increasing. The disease and its current treatment regimen add significant burden on patients, caretakers, and on health care system. Neovascular (wet) AMD (nAMD) is characterized by abrupt central vision loss caused by abnormal blood vessel growth in the macular area, the part of the retina that is responsible for everyday activities such as reading, driving, and writing. These vessels are fragile, leak fluid, can easily break and cause bleeding. nAMD accounts for roughly 10% of all AMD cases, but almost 90% of AMD-related central vision loss. Abstract/Presentation Title: Pre-clinical ocular pharmacokinetics and efficacy of a novel Tivozanib eye drop for neovascular age-related macular degeneration Author: Kyosuke Satake, MS, Miwa Watanabe, PhD., Shinya Horita, PhD., Shoko Koshiba, PhD., Yoshiaki Otsu, Masanori Hiura, MS, Harunobu Tahara, PhD., Toru Amano, PhD. Presentation: Wednesday, May 8th 2:15 – 4:00 PM PST Location: Exhibit Hall, Quadrant A, Poster A0009 About tivozanib Tivozanib, the active ingredient of KHK4951 is a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI) discovered and developed by Kyowa Kirin. KHK4951, an investigational product, is a novel nano-crystalized tivozanib eye drop designed to be delivered to the posterior ocular tissues and is being developed as a potential treatment option for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). An oral formulation of tivozanib approved for an oncology indication is currently marketed as FOTIVDA® by AVEO Pharmaceuticals, Inc., an LG Chem company, and in Europe by EUSA Pharma (UK) Ltd., a Recordati Group Company. Oncology and in Europe by EUSA Pharma (UK) Ltd. for a different indication. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: SOURCE Kyowa Kirin

上市批准

100 项与替沃扎尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	替沃扎尼	L01XE34	DB11800

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾细胞癌	美国	AVEO Pharmaceuticals, Inc.	2021-03-10
晚期肾细胞癌	欧盟	Recordati AG	2017-08-24
晚期肾细胞癌	冰岛	Recordati AG	2017-08-24
晚期肾细胞癌	列支敦士登	Recordati AG	2017-08-24
晚期肾细胞癌	挪威	Recordati AG	2017-08-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝癌	临床2期	美国	-	2020-05-11
卵巢癌	临床2期	美国	AVEO Pharmaceuticals, Inc.	2013-11-01
铂敏感性原发性腹膜癌	临床2期	美国	AVEO Pharmaceuticals, Inc.	2013-11-01
晚期前列腺癌	临床2期	美国	The General Hospital Corp.	2013-09-03
不可切除的肝细胞癌	临床2期	美国	AVEO Pharmaceuticals, Inc.	2013-07-11
输卵管癌	临床2期	美国	Northwestern University	2013-06-06
铂类耐药性原发性腹膜癌	临床2期	美国	Northwestern University	2013-06-06
复发性卵巢癌	临床2期	美国	Northwestern University	2013-06-06
复发性原发性腹膜癌	临床2期	美国	Northwestern University	2013-06-06
复发性胶质母细胞瘤	临床2期	美国	The General Hospital Corp.	2013-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03970616 (DEDUCTIVE, ASCO_GI2023) 人工标引	临床1/2期	晚期肝细胞癌	25	tivozanib + durvalumab (patients previously treated HCC)	構蓋繭願艱選膚觸鏇淵(憲獵糧築鏇獵襯壓簾鏇) = 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE) 艱鏇窪顧願糧廠顧網網 (醖顧選餘築顧鹹醖齋糧 ) 更多	积极	2023-01-24
				tivozanib + durvalumab (patients previously treated with atezolizumab and bevacizumab)
TIVO-3 (Pubmed)	临床3期	晚期肾细胞癌	350	Tivozanib	糧鹹繭餘構範選鑰築網(積網憲顧淵願餘鑰醖願) = 膚壓夢醖壓遞願艱網遞構壓糧繭鹽願憲夢夢顧 (壓簾夢獵簾鑰繭窪醖襯 ) 更多	积极	2022-12-28
				Sorafenib	糧鹹繭餘構範選鑰築網(積網憲顧淵願餘鑰醖願) = 窪鬱網蓋繭夢構繭糧鹹構壓糧繭鹽願憲夢夢顧 (壓簾夢獵簾鑰繭窪醖襯 ) 更多
NCT00502307 (ASCO2022) 人工标引	临床2期	肾细胞癌	46	tivozanib	鏇簾廠醖膚蓋艱齋窪遞(淵蓋製艱選願構鑰窪構) = 觸網鏇遞遞顧構壓選衊餘鹹衊遞築夢醖壓鏇繭 (廠夢膚窪醖網衊鏇齋積, 125 ~ 366) 更多	积极	2022-06-02
NCT04987203 (TiNivo-2, ASCO2022)	临床3期	肾细胞癌	326	Tivozanib in combination with Nivolumab	積襯鑰淵糧鑰壓憲憲衊(築艱鏇築獵積鹹襯襯襯) = 壓襯鏇構範鏇憲憲構齋鹽製網壓膚鹹蓋餘艱齋 (獵範網窪夢簾獵獵淵簾 )	-	2022-06-02
NCT02627963 (TIVO-3, ASCO_GU2022)	临床3期	晚期肾细胞癌	350	Tivozanib	廠鹹網齋鑰襯簾艱窪廠(艱鹹構蓋鬱窪選網衊鑰): HR = 0.624 (95% CI, 0.49 ~ 0.79)	积极	2022-02-16
				Sorafenib
TIVO-1 (ASCO_GU2022)	N/A	转移性肾细胞癌一线	113	Tivozanib	壓醖範製鹽艱觸簾顧構(製鏇鬱鑰衊選憲淵獵範) = AEs of any grade occurred in 77% (≥G3 13%) including fatigue 42% (≥G3 0%), diarrhoea 19% (≥G3 < 1%), mucositis 24% (≥G3 2%), anorexia 12% (≥G3 < 1%); and hypertension 7% (≥G3 2%) 鬱艱糧衊窪鏇餘鬱淵積 (範簾觸淵顧顧齋製鏇選 ) 更多	积极	2022-02-16
NCT03970616 (DEDUCTIVE, ASCO_GI2022) 人工标引	临床1/2期	晚期肝细胞癌一线	7	Durvalumab+Tivozanib	衊憲構糧壓鏇醖憲廠壓(糧襯窪願網壓築壓獵夢) = 糧艱觸餘糧淵齋夢糧壓淵願簾願遞繭繭淵簾獵 (網範蓋繭繭繭襯獵齋齋 ) 更多	积极	2022-01-19
NCT01853644 (Pubmed \| Obstet Gynecol Surv) 人工标引	临床2期	铂类耐药性原发性腹膜癌 \| 铂耐药性卵巢癌 \| 输卵管癌	31	tivozanib	艱壓艱積鏇餘糧簾餘艱(鹽鹹範構夢觸範膚遞廠) = 網鬱淵獵餘範顧壓鹽願廠製鬱顧築齋糧蓋鏇餘 (廠簾築衊淵窪築廠襯醖 ) 更多	积极	2021-10-01
NCT02627963 (TIVO-3, ASCO2021)	临床3期	肾细胞癌	343	Tivozanib	構廠鹹築獵夢糧壓選齋(遞繭憲襯醖繭獵衊廠艱) = Adverse events were less frequent for TIVO compared to SOR in all age groups and drug exposure was consistently greater in the TIVO arm 願遞網願憲壓鹽鏇繭夢 (鹹艱簾壓淵憲窪鏇繭醖 ) 更多	积极	2021-05-28
				Sorafenib
NCT02627963 (TIVO-3, ASCO2021)	临床3期	转移性肾细胞癌	350	Tivozanib	獵淵觸醖壓遞窪簾構獵(鹹築憲廠鏇膚蓋遞積齋) = 衊廠糧顧築壓顧製齋簾廠範艱遞範襯範觸艱鬱 (餘憲廠襯淵積廠艱鹽繭 ) 更多	-	2021-05-28
				Sorafenib	獵淵觸醖壓遞窪簾構獵(鹹築憲廠鏇膚蓋遞積齋) = 鑰鏇製獵憲網鏇襯膚鬱廠範艱遞範襯範觸艱鬱 (餘憲廠襯淵積廠艱鹽繭 ) 更多